APTORUM

NASDAQ: **APM**

Market Data

Aptorum Group

NASDAQ: **APM**

Fiscal Year	December
Industry	Biotechnology
Recent Price	$1.00
Market Cap	$35.7M
Shares Out.	35.7M
Float	9.1M
Avg. Volume (90-day)	124K
Revenue (ttm)	$1.54M
Cash (mrq)[1]	$8.13M
LT Debt (mrq)[1]	$0.0M

As of May 10, 2022

[1] as of December 31, 2021

aptorumgroup.com

Corporate Headquarters
17 Hanover Square,
London, W1S 1BN, United Kingdom
Tel: +44 20 8092 9299

US Investor Relations Contact
Dave Gentry, CEO
RedChip Companies, Inc.
Tel: +1 407-491-4498
dave@redchip.com

Stock Transfer Agent
Continental Stock Transfer & Trust
1 State Street Plaza, 30th Floor
New York, NY 10004

Company Overview

Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases. The Company launched two new clinical trials in 2021. Aptorum's Smart-ACT™ platform is designed to bring an average of three drug candidates for orphan diseases to clinical trials every 12-18 months. The Company is now preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman's health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.

Value Proposition

Aptorum's four core assets (RPIDD, SACT-1, ALS-4, NLS-2) target indications with a combined market value of more than $250 billion. The company is building a diverse portfolio of over 12 projects primarily in therapeutics and diagnostics across a wide range of unmet disease areas. Aptorum translates early-stage discovery into proof-of-concept clinical stages and transforms clinical outcomes through licensing, co-development, and commercialization. The company's proprietary Smart-ACT™ platform combines a computational approach and wet lab validation to screen over 2,600 approved small molecule drugs. This process allows Aptorum to identify candidates that can be repurposed for selected orphan or unmet diseases. This platform's first proof-of-concept asset is SACT-1 for Neuroblastoma, a cancer mostly affecting children that develops from immature nerve cells. The Company announced positive data from its recently completed Phase 1 trial of SACT-1 for Neuroblastoma in May 2022. SACT-1 was also recently used to identify at least three small molecule drugs targeting COVID-19, which Aptorum is investigating in collaboration with Covar Pharmaceuticals and the University of Hong Kong's Microbiology Department.

Current Discovery & Development Pipeline

Project	Candidate / Modality	Indication	Development Stage
Acticule's Series			Target identification & Selection · Lead Discovery · Lead Optimization · IND (Or IND equivalent Enabling) · Clinical Trial Application Submission · Phase I · Phase II / III
ALS-4	Small molecule	Treatment of bacterial infections caused by Staphylococcus aureus including MRSA	
SACT's Series			Computational Discovery · *In Vitro* Validation · Existing PhI/II Clinical Safety Data[1] · *In Vivo* Validation · IND Preparation & Submission · Phase I · Phase Ib / IIa
SACT-1	Repurposed small molecule	Neuroblastoma and other potential cancer types	
RPIDD			Development and Experimentation · Product Optimization · Clinical validation & Pre-Commercialization preparation · Commercial-ization
RPIDD	Liquid biopsy rapid pathogen diagnostics	Pathogen molecular diagnostics	

Project	Modality	Target Customer	Formulation	Commercialization and Distribution
NativusWell® DOI (NLS-2)[2]	Dietary Supplement	Women undergoing menopause		

Project	Candidate / Modality	Indication	Development Stage
SACT's Series			Computational Discovery · *In Vitro* Validation · Existing PhI/II Clinical Safety Data[1] · *In Vivo* Validation · IND Preparation & Submission · Phase I · Phase Ib / IIa
SACT - COV19	Repurposed small molecule	Coronavirus Disease 2019 (COVID-19)	
SACT-2	Repurposed small molecule	To be disclosed	
SACT-3	Repurposed small molecule	To be disclosed	
Acticule's Series			Target identification & Selection · Lead Discovery · Lead Optimization · IND (Or IND equivalent Enabling) · Clinical Trial Application Submission · Phase I · Phase II / III
ALS-1	Small molecule	Treatment of viral infections caused by influenza virus A	
ALS-2/3	Small molecule	Treatment of gram+ve bacterial infections	
Discovery Stage			
DLS-1+2	Small molecule & Degraders	NSCLC with mutation	
DLS-3	Small molecule	Autoimmune	

Investment Highlights

- Four core assets showing significant progress:
  - **Rapid Pathogen Identification and Detection Diagnostics ("RPIDD")** technology, a rapid, accurate, cost-effective and untargeted method to identify and detect existing or emerging unknown pathogens through liquid biopsy. Such unknown pathogens include DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria, fungi, etc.
  - **SACT-1,** a repurposed drug candidate for treating neuroblastoma discovered through its Smart-ACT™ drug discovery platform; received Orphan Drug Designation for SACT-1 in January 2022
  - **ALS-4,** a small drug molecule candidate for the treatment of infections caused by *Staphylococcus aureus* including *Methicillin-resistant Staphylococcus aureus* (MRSA)
  - **NLS-2,** a dietary supplement for the relief of menopausal symptoms.
- Clinical trials:
  - Recently completed Phase 1 trial SACT-1 for neuroblastoma treatment (global c. $2.6 billion market); trial generated positive safety and bioavailability data to advance program
  - ALS-4 for Staphylococcus aureus (incl. MRSA) saw positive interim results for Phase 1 trial (global c.$3.0 billion market) with no Serious Adverse Events (SAE) or clinically relevant changes in vital signs
- Near-term commercialization of dietary supplement for woman's menopausal health (global c. $17 billion supplement market)
- Three additional SACT programs underway, including investigation of at least three repurposed drug candidates for coronavirus (COVID-19) in collaboration with Covar Pharmaceuticals and The University of Hong Kong
- 12+ therapeutic candidates under development in areas including infectious diseases, gastrointestinal microbiome, and drug repurposing for orphan diseases; representing a combined over $8 billion+ global market opportunity
- Expanding IP protections; two new patents granted in Q1 2022
- Over 50+ staff, clinical advisors, and consultants with vast experience in drug development and clinical trials, including US FDA, EMA, and NMPA purposes.